small win: hepatic fat stopped being a problem at week 91
Check-in as promised in the title: small win: hepatic fat stopped being a problem at week 91. Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use. Independent purity results for this compound are very sparse across the whole site, which means any impression…
How fast was the escalation in that protocol?
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.
the weight numbers are secondary to what this is being developed for
dual GLP-1 and glucagon agonist, and the glucagon arm is the story
Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.
Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis wit
Disagreeing with this bit: that number comes from a different programme with a different population.
Are you reading the publication or a summary?
Yes — nothing containing this is approved anywhere, which is the first fact and usually the last one mentioned.